Mederma
Mederma® PM Intensive Overnight Scar Cream is a new scar
cream formulated to work at night. Mederma® PM is clinically
shown to improve the overall appearance, size, color, and
texture of scars, making them softer, smoother, and less noticeable.
Mederma reports that subjects who used Mederma® PM
for 8 weeks as directed saw noticeable improvement in the size
of scars in as little as 2-4 weeks and a 50% reduction in the size
of the scars after 8 weeks. The cream is also formulated with
Tripeptolâ„¢, a skin-nourishing complex with peptides, collagen,
and antioxidants that complement the increased nighttime regeneration
of the skin to promote healthy looking skin.
Mederma® PM is available in the First Aid and Skin Care sections
of drugstores. Mederma® PM may be used on scars on the face
and the body resulting from injury, cuts, surgery, burns and acne.
For best results, Mederma® PM should be applied evenly and gently
rubbed into the scar once nightly for eight weeks on new scars
and once nightly for three to six months on existing scars.
Quinnova Pharmaceuticals and Ecoza (Econazole Nitrate) Topical Foam, 1%
Quinnova Pharmaceuticals has announced the launch of its
FDA-approved Ecoza (econazole nitrate) topical foam, 1%.
Ecoza foam is indicated for the treatment of interdigital tinea
pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes,
and Epidermophyton floccosum in patients 12 years
of age and older.
Quinnova touts Ecoza foam as a novel alternative for the treatment
of interdigital tinea pedis (athletes foot between the toes),
combines the proven antifungal efficacy of econazole nitrate
with the skin-restoring properties of Proderm Technology. The
company claims that the foam is proven to kill fungi that cause
interdigital tinea pedis when applied once-daily for 4 weeks.
In two double-blind, parallel-group, vehicle-controlled, multicenter
clinical trials, 495 subjects aged 12 years with a clinical
diagnosis of interdigital tinea pedis and fungal culture positive
for a dermatophyte at baseline received ecoza foam (n=246)
or foam vehicle (n=249). Subjects applied ecoza foam or foam
vehicle once daily for 4 weeks. The primary endpoint was proportion
of subjects who achieved a complete cure (negative
KOH, negative fungal culture, no evidence of clinical disease
as indicated by complete resolution of all signs and symptoms)
at 2 weeks post-treatment (Day 43). Secondary endpoints included
mycologic cure (negative KOH and negative culture)
and effective treatment (mycologic cure + no or mild erythema
and/or scaling and all other signs and symptoms absent).
The results from the clinical studies demonstrated that ecoza
foam exhibited superiority over foam vehicle for the primary
and secondary endpoints and demonstrated potent antifungal
activity against all of the pathogens evaluated with a high mycologic
cure rate. The complete cure rate at Day 43 (2 weeks
post-treatment) was higher in the ecoza foam group (24.3%) than
in the foam vehicle group (3.6%). In addition, higher rates of mycologic
cure (67.6% vs 16.9%) and effective treatment (48.6% vs
10.8%) were observed with econazole nitrate foam 1% versus
the foam vehicle. Ecoza foam was safe and well tolerated with a
safety profile comparable with the foam vehicle. During clinical
trials with Ecoza foam the most common adverse reactions were
application site reactions, which occurred in less than 1% of subjects
in both the Ecoza foam and vehicle arms.
Induction of Systemic Immunity Following Treatment of Tumors With PV-10
Provectus Biopharmaceuticals, Inc. a development-stage oncology
and dermatology biopharmaceutical company, reports
that on April 6, 2014, researchers from the Moffitt Cancer
Center presented a poster presentation detailing significant decrease
in melanoma cells in patients’ injected tumors 7-14 days
after intralesional PV-10 treatment that was accompanied by
similar decrease in uninjected bystander tumors. These clinical
and pathologic changes were accompanied by increases
in important immune cell populations detected in the patients’
peripheral blood. The poster presentation, based upon abstract
#630, entitled “Induction of anti-melanoma immunity after intralesional
ablative therapy,†was authored by Hao Liu, Krithika
Kodumudi, Amy Weber, Amod A. Sarnaik and Shari Pilon-
Thomas of the Moffitt Cancer Center.
Provectus’ investigational drug PV-10, a 10% solution of Rose
Bengal, is currently being studied as a novel cancer therapeutic,
and Provectus has applied to the FDA for breakthrough therapy
designation of PV-10 for the treatment of melanoma based
on a 7 center international single-arm trial. PV-10 is designed
to selectively target and destroy cancer cells without harming
surrounding healthy tissue, significantly reducing potential for
systemic side effects. In melanoma patients, intralesional (IL) injection
of PV-10 has led to regression of injected lesions as well
as uninjected metastases. The mechanism of regression of uninjected
lesions is under investigation at Moffitt Cancer Center
The Moffitt researchers presented clinical data on 8 melanoma
patients that demonstrated significant decreases in melanoma
cells in injected tumors and uninjected bystander tumors 7-14
days after PV-10 injection as evidenced by pathologic evaluation
confirmed with immunohistochemical staining of biopsy
